Monica Carbajales-Alvarez

Monica Carbajales-Alvarez

Auto-generated profile, based on publicly available information

Monica Carbajales-Alvarez

Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2005 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
NGN. Granizo
N. Granizo
MÁM. Álvarez
M. Álvarez
MMercedes Valiente
Mercedes Valiente

2 June 2019 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
RPRubén Pampín
Rubén Pampín
YLYoar Labeaga
Yoar Labeaga
BRBelén Rodríguez
Belén Rodríguez
BFBeatriz Fernández
Beatriz Fernández
RFRubén Fernández
Rubén Fernández
MCMónica Carbajales
Mónica Carbajales
Background: We describe the feasibility and safety of an oral administration schedule of hydration, alkalinization and leucovorin rescue with an ambulatory high-dose methotrexate regimen. Methods: Single-centre prospective observational study conducted within a tertiary hospital where all patients have received systemic high-dose methotrexate (3.5 g/m2). Patients were instructed to keep an adequate ambulatory oral hydration and alkalinization to monitor urine pH and to adjust bicarbonate according to our institution's treatment protocol. High-dose methotrexate was infused over 4 h. Urine pH was checked before high-dose methotrexate administration, and for any value less than 7 a sodium bicarbonate bolus was given. Leucovorin at a standard dose was begun 24 h after high-dose methotrexate. methotrexate serum concentrations were monitored daily from 24 h after administration until clearance (level ≤ 0.1 µmol/L). Results: From January 2016 to June 2018, 49 ambulatory high-dose methotrexate courses were given to 18 patients. No dose reduction was required afterwards. All patients completed succesfully the planned three doses in an outpatient basis, except four patients, one of them due to pneumonitis. Previous to methotrexate infusion, urinary pH > 7 was achieved in 35 (79.5%) cycles. Methotrexate clearance was achieved by 72 h in 35 courses (71.4%), and by 96 h in 100%. Neutropenia/trombocytopenia grades III/IV were observed in four cycles (8.16%) and two (4.08%) cycles, respectively. Around 20.40% were associated with stomatitis, 14.20% vomiting, 10.20% asthenia, 8.16% diarrhea and 6.12% with renal toxicity. Conclusions: Ambulatory administration of high-dose methotrexate as CNS prophylaxis is safe and feasible following the described approach, allowing us to optimize healthcare resources.

1 August 2002 in Infection
Verified
Journal Article
Closed access
PDF file
VICTOR ASENSIVICTOR ASENSI
VICTOR ASENSI
MAM Alvarez
M Alvarez
JCJ A Carton
J A Carton
MLM Lago
M Lago
JMJ A Maradona
J A Maradona
JAJ M Arribas
J M Arribas

17 June 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CCC. Carriles
C. Carriles
PFPaula Jimenez Fonseca
Paula Jimenez Fonseca
MSM. Sánchez-Cánovas
M. Sánchez-Cánovas
PPP. Pimentel
P. Pimentel
ABAlberto Carmona Bayonas
Alberto Carmona Bayonas
ALAna Lozano-Blázquez
Ana Lozano-Blázquez

1 July 2014 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
ALAna Lozano-Blázquez
Ana Lozano-Blázquez
CCCecilia Calvo-Pita
Cecilia Calvo-Pita
MCMonica Carbajales-Alvarez
Monica Carbajales-Alvarez
PSPatricio Suarez-Gil
Patricio Suarez-Gil
FMFernando Martinez-Martinez
Fernando Martinez-Martinez
MCMiguel Angel Calleja
Miguel Angel Calleja
Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice Ana Lozano-Blázquez,1 Cecilia Calvo-Pita,2 Mónica Carbajales-Álvarez,1 Patricio Suárez-Gil,3 Fernando Martínez-Martínez,4 Miguel Ángel Calleja-Hernández51Pharmacy Department, Hospital de Cabueñes, Gijón, Spain; 2Pharmacy Department, Primary Health Care, Servicio Madrileño de Salud, Dirección Asistencial Oeste, Madrid, Spain; 3Research Unit Área V, Hospital de Cabueñes, Gijón, Spain; 4Responsable del Grupo de Investigación en Atención Farmacéutica, Universidad de Granada, 5UGC Provincial de Farmacia de Granada Instituto de Biomedicina de Granada, Hospital Virgen de las Nieves, Granada, SpainBackground: In Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.Methods: This was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria.Results: The PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma.Conclusion: The degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.Keywords: decision-making, drug selection, drug utilization, formulary, neoplasm, Pharmacy and Therapeutics committee